Literature DB >> 15368921

A correlation study of quinoline derivatives and their pharmaceutical behavior by ab initio calculated NQR parameters.

Marjan A Rafiee1, Nasser L Hadipour, Hossein Naderi-manesh.   

Abstract

In this paper, ab initio calculated NQR parameters for some quinoline-containing derivatives are presented. The calculations are carried out in a search for the relationships between the charge distribution of these compounds and their ability to interact with haematin. On the basis of NQR parameters, pi-electron density on the nitrogen atom of the quinoline ring plays a dominant role in determining the ability of quinolines to interact with haematin. This point was confirmed with investigation of Fe+3 cation-pi quinoline ring interactions in 2- and 4-aminoquinoline. However, our results do not show any preference for those carbon atoms of the quinoline ring which previous reports have noted. In order to calculate the NQR parameters, the electric field gradient (EFG) should be evaluated at the site of a quadrupolar nucleus in each compound. EFGs are calculated by the Gaussian 98 program using the B3LYP/6-31 G* level of theory.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15368921     DOI: 10.1023/b:jcam.0000035201.67977.16

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  11 in total

1.  The iron environment in heme and heme-antimalarial complexes of pharmacological interest.

Authors:  P A Adams; P A Berman; T J Egan; P J Marsh; J Silver
Journal:  J Inorg Biochem       Date:  1996-07       Impact factor: 4.155

2.  Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density.

Authors: 
Journal:  Phys Rev B Condens Matter       Date:  1988-01-15

3.  Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of beta-hematin formation, and antiplasmodial activity.

Authors:  T J Egan; R Hunter; C H Kaschula; H M Marques; A Misplon; J Walden
Journal:  J Med Chem       Date:  2000-01-27       Impact factor: 7.446

4.  Structural specificity of chloroquine-hematin binding related to inhibition of hematin polymerization and parasite growth.

Authors:  S R Vippagunta; A Dorn; H Matile; A K Bhattacharjee; J M Karle; W Y Ellis; R G Ridley; J L Vennerstrom
Journal:  J Med Chem       Date:  1999-11-04       Impact factor: 7.446

5.  Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites.

Authors:  A C Chou; R Chevli; C D Fitch
Journal:  Biochemistry       Date:  1980-04-15       Impact factor: 3.162

6.  The quinine-haemin interaction and its relationship to antimalarial activity.

Authors:  D C Warhurst
Journal:  Biochem Pharmacol       Date:  1981-12-15       Impact factor: 5.858

7.  Thermodynamic factors controlling the interaction of quinoline antimalarial drugs with ferriprotoporphyrin IX.

Authors:  T J Egan; W W Mavuso; D C Ross; H M Marques
Journal:  J Inorg Biochem       Date:  1997-11-01       Impact factor: 4.155

8.  A ferriprotoporphyrin IX-chloroquine complex promotes membrane phospholipid peroxidation. A possible mechanism for antimalarial action.

Authors:  Y Sugioka; M Suzuki; K Sugioka; M Nakano
Journal:  FEBS Lett       Date:  1987-11-02       Impact factor: 4.124

Review 9.  Structure-function relationships in chloroquine and related 4-aminoquinoline antimalarials.

Authors:  T J Egan
Journal:  Mini Rev Med Chem       Date:  2001-05       Impact factor: 3.862

10.  Further evidence for the interaction of the antimalarial drug amodiaquine with ferriprotoporphyrin IX.

Authors:  G Blauer; M Akkawi; E R Bauminger
Journal:  Biochem Pharmacol       Date:  1993-11-02       Impact factor: 5.858

View more
  1 in total

1.  A theoretical study of benzaldehyde derivatives as tyrosinase inhibitors using Ab initio calculated NQCC parameters.

Authors:  Marjan Rafiee; Masoumeh Javaheri
Journal:  Mol Biol Res Commun       Date:  2015-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.